288 related articles for article (PubMed ID: 30184133)
1. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
Furey ML; Drevets WC
Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
[TBL] [Abstract][Full Text] [Related]
3. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
Furey ML; Khanna A; Hoffman EM; Drevets WC
Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
[TBL] [Abstract][Full Text] [Related]
5. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
[TBL] [Abstract][Full Text] [Related]
6. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
Guo W; Machado-Vieira R; Mathew S; Murrough JW; Charney DS; Grunebaum M; Oquendo MA; Kadriu B; Akula N; Henter I; Yuan P; Merikangas K; Drevets W; Furey M; Mann JJ; McMahon FJ; Zarate CA; Shugart YY
Transl Psychiatry; 2018 Dec; 8(1):280. PubMed ID: 30552317
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.
Ellis JS; Zarate CA; Luckenbaugh DA; Furey ML
J Affect Disord; 2014 Jun; 162():39-42. PubMed ID: 24767003
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of intranasal ketamine in major depressive disorder.
Lapidus KA; Levitch CF; Perez AM; Brallier JW; Parides MK; Soleimani L; Feder A; Iosifescu DV; Charney DS; Murrough JW
Biol Psychiatry; 2014 Dec; 76(12):970-6. PubMed ID: 24821196
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
[TBL] [Abstract][Full Text] [Related]
12. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
13. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
[TBL] [Abstract][Full Text] [Related]
14. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.
Drevets WC; Furey ML
Biol Psychiatry; 2010 Mar; 67(5):432-8. PubMed ID: 20074703
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder.
Chen JCC; Sumner RL; Naga VK; Hoeh N; Ayeni HA; Singh V; Wilson A; Campbell D; Sundram F; Muthukumaraswamy SD
J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35980261
[No Abstract] [Full Text] [Related]
16. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
17. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Yu JJ; Pei LB; Zhang Y; Wen ZY; Yang JL
J Clin Psychopharmacol; 2015 Aug; 35(4):406-10. PubMed ID: 26066335
[TBL] [Abstract][Full Text] [Related]
18. Baseline mood-state measures as predictors of antidepressant response to scopolamine.
Furey ML; Nugent AC; Speer AM; Luckenbaugh DA; Hoffman EM; Frankel E; Drevets WC; Zarate CA
Psychiatry Res; 2012 Mar; 196(1):62-7. PubMed ID: 22349648
[TBL] [Abstract][Full Text] [Related]
19. Disentangling the association of depression on the anti-fatigue effects of ketamine.
Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
